SCHEMBL2984402

SCHEMBL2984402

COc1cc2c(nc1OC)c(-c1cc3c(Cl)ccnc3[nH]1)cn2C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.51
GSK3B P49841 4/20 0.42
GSK3A P49840 3/20 0.42
CDK7 P50613 3/20 0.42
LRRK2 Q5S007 3/20 0.42
AURKB Q96GD4 3/20 0.42
LCK P06239 2/20 0.42
JAK2 O60674 2/20 0.42
BTK Q06187 1/20 0.42
CDK9 P50750 11/20 0.37
CDK5 Q00535 3/20 0.37
PIM1 P11309 2/20 0.37
MAPK8 P45983 2/20 0.37
AURKA O14965 2/20 0.37
ABL1 P00519 2/20 0.37
RET P07949 2/20 0.37
FLT3 P36888 2/20 0.37
LIMK1 P53667 2/20 0.37
PRKAA1 Q13131 2/20 0.37
CLK4 Q9HAZ1 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541427 0.88 IGF1R (0.41) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL2982565 0.87 IGF1R (0.53) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL2992440 0.86 IGF1R (0.49) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL2985996 0.85 IGF1R (0.48) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL2987277 0.85 IGF1R (0.48) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL2982560 0.85 IGF1R (0.48) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL2992621 0.84 CDK9 (0.42) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL2985873 0.84 IGF1R (0.38) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL2989437 0.84 CCNT1 (0.42) IGF1RCDK9MAPK8CCNT1CHUK
SCHEMBL27714423 0.84 IGF1R (0.38) IGF1RCDK9PIM1MAPK8CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799691-B1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-12-21 EP claimed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US claimed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US claimed
EP-1799691-B1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-12-21 EP disclosed
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 IGF1R 606/4885GSK3B 438/4885GSK3A 459/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 IGF1R 606/4885GSK3B 438/4885GSK3A 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.